Artelo Biosciences (ARTL) announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences, is presenting expanded data from Artelo’s lead Fatty Acid Binding Protein 5 inhibitor, ART26.12, Single Ascending Dose, SAD, Study at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit, taking place October 15-16, 2025, in Boston, Massachusetts. In addition, Professor O’Sullivan will be giving additional insights on ART27.13 development progress in cancer-related anorexia with interim data from the Phase 2 portion of the Cancer Appetite Recovery Study, CAReS.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo prices 441,210 shares at $4.40 in underwritten public offering
- Artelo Biosciences files to sell common stock, no amount given
- Artelo Biosciences presents interim Phase 2 CAReS data on ART27.13
- Artelo Biosciences Completes Stock Offering with Over-Allotment
- Artelo Biosciences announces publication of preclinical data on ART12.11